+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Veterinary Anti-infectives Market - Growth, Trends, and Forecast (2020 - 2025)

  • PDF Icon


  • 120 Pages
  • February 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4987290
UP TO OFF until Mar 31st 2024
The prevention and treatment of deadly animal diseases are key market indicators for veterinary anti-infectives. Certain factors such as increasing zoonotic and foodborne diseases, rising pet ownership and rising R&D activities in animal healthcare. The zoonotic and foodborne diseases are naturally transmitted from animals to humans, due to the consumption of contaminated food and water, exposure to the pathogen during preparation, processing, or by direct contact with infected animals or humans. Zoonotic diseases are quite common around the world. According to the scientists of Centers for Disease Control and Prevention (CDC), over 6 out of every 10 known infectious diseases in humans are spread via animals, moreover, 3 out of every 4 new or emerging infectious diseases are spread from animals. So, it is evident that these diseases are major public health problem worldwide. Thus, increasing burden of zoonotic diseases is expected to impact the growth of the market.

Key Market Trends

Cattle Sub-Segment is Expected to Show Better Growth in the Forecast Years

Based on Animal Type, it is segmented into cattle, poultry, cats, dogs and other animals. The growth of the cattle sub-segment is mainly attributed to the high population of cattle across the world and the dominance of cattle farming as a major income source for people in many countries. For example, in countries such as China and Mexico where the livestock population is high, the market for cattle anti-infective products is larger compared to the developed countries. According to the Food and Agriculture Organization (FAO), the worldwide population of cattle is more than 1.4 billion, out of which a large proportion is noted in countries such as India, Brazil, and China. Furthermore, in 2019, Bimeda received FDA approval for OxyMed LA indicated to treat bacterial enteritis in swine and cattle. Hence, new product approval, awareness about cattle diseases and zoonosis are anticipated to have a positive impact on the market in the coming years.

North America Dominates the Veterinary Anti-infectives Market

North America region is among the major contributor to livestock and the implementation of animal healthcare benefits across the region. The market is growing rapidly due to the presence of advanced animal healthcare programs coupled with awareness regarding animal health is projected to drive the regional market growth. According to 2017 data by the North American Meat Institute, the poultry and meat industries are the largest division of the United States agriculture sector. Moreover, rising disease burden in animals is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the veterinary anti-infectives market are – Bayer AG, Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco, Merck & Co Inc., Phibro Animal Health Corporation, Vetoquinol S.A., Virbac and Zoetis Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Zoonotic and Foodborne Diseases
4.2.2 Rising Pet Ownership
4.2.3 Rising R&D Activities in Animal Healthcare
4.3 Market Restraints
4.3.1 Use of Counterfeit Medicines
4.3.2 Increasing Cost of Veterinary Services
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Animal Type
5.1.1 Cattle
5.1.2 Poultry
5.1.3 Cats
5.1.4 Dogs
5.1.5 Other Animals
5.2 By Product Type
5.2.1 Antibacterial
5.2.2 Antivirals
5.2.3 Antifungals
5.2.4 Others
5.3 By Mode of Administration
5.3.1 Oral
5.3.2 Topical
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Boehringer Ingelheim GmbH
6.1.3 Ceva Sante Animale
6.1.4 Elanco
6.1.5 Merck & Co Inc.
6.1.6 Phibro Animal Health Corporation
6.1.7 Vetoquinol S.A.
6.1.8 Virbac
6.1.9 Zoetis Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ceva Sante Animale
  • Elanco
  • Merck & Co Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.